Kornimate/medical-research-clean huggingface dataset:
is deltoid ligament repair for ankle fracture necessary?

Conditions: Ankle Fracture

Summary: the investigator hypothesizes that primary acute ankle deltoid ligament repair can help restore ankle radiographic congruity and functional outcomes.

the purpose of this study is to evaluate whether stabilization with anatomic ankle deltoid ligament repair can help restore ankle congruity and improve functional outcome in patients with unstable supination-external rotation ankle fractures.

Eligibility criteria:
inclusion criteria: * supination-external rotation ankle fracture with deltoid ligament incompetency * minimum of 2 year clinical follow up exclusion criteria: * non-supination-external rotation ankle fracture * medial malleolus fracture * incomplete clinical or radiographic followup.
tracking early emergence of sound perception impairments in fxs with multimodal fnirs/eeg- infant

Conditions: Fragile X Syndrome

Summary: individuals with fragile x syndrome show differences in how they understand and learn language from infancy. they frequently have lifelong delays in speech and language as well. in addition, they experience other auditory symptoms, including being very sensitive to certain sounds as well as being more sensitive than others to loud sounds. the underlying brain activity for sound perception and speech learning in fragile x is not well understood, especially in the infant and toddler years. this study uses behavioral assessment of speech and language abilities, neuroimaging, and hearing tests to understand how speech and hearing are different in children with fragile x syndrome.

fragile x syndrome (fxs) is the leading monogenic cause of intellectual disability and autism and is associated with extremely high risk for early delays in speech and language. while infancy is essential for speech and language development, neural mechanisms for language impairments have been studied entirely in older children and adults with fxs. therefore, markers for speech and language impairments are unavailable in infants and toddlers with fxs to predict severity, test potential mechanisms, and track response to intervention. the investigators have identified a hallmark brain-based phenotype of hyperresponsiveness to sounds in adolescents and adults with fxs. this fundamental alteration in cortical responses to sound could influence early language delays, but this phenotype has not been explored in infants or toddlers with fxs. specifically, in this study the investigators will use simultaneous eeg/fnirs during presentation of simple speech, stories, and nonspeech sounds to quantify and localize auditory hypersensitivity and neural differentiation in 30 infants and toddlers, including 15 with fxs and 15 controls. infants will complete visits at different ages, with possible visits at 6 months, 12 months, 18 months, and 24 months, so that changes with development can be tracked over time.

Eligibility criteria:
inclusion criteria: * diagnoses of fragile x syndrome, typical development, or history of premature birth * able to sit independently * english is spoken at home exclusion criteria: * for all participants: no seizures in the past 6 months * for typical development group and fragile x group: not born prior to 32 weeks gestation
heart rate monitoring by wearable devices in graves' disease

Conditions: Graves' Disease in Remission (Disorder)

Summary: a multi center randomized controlled study including 3 arms (wearable device group, control group 1, control group 2). this study is to investigate clinical feasibility of heart rate monitoring using wearable devices to detect disease recurrence in the patients who discontinue anti-thyroid drugs in remission state.

a multi center randomized controlled study including 3 arms (wearable device group, control group 1, control group 2). study participants: patients with graves' disease who are planned to discontinue anti-thyroid drugs in remission state wearable device group: participants use wearable device and their heart rate and activity are monitored. if their resting heart rate (rhr) increase beyond the set range or they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. if their rhr stay within set range and they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs. control group 1: participants don't use wearable devices. if they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. if they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs. control group 2: participants don't use wearable devices. if they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. if they have no symptoms and signs, they come to hospital and get tests for thyroid function 3 and 6 months after discontinuing anti-thyroid drugs. a period to detecting disease recurrence, thyroid function test and hyperthyroid symptom scale (hss) at the time of disease recurrence, and the number of hospital visit and medical cost until detecting disease recurrence will be compared among 3 groups.

Eligibility criteria:
inclusion criteria: * patients with graves' disease who are being treated with anti-thyroid drugs (atds) and planned to discontinue atds * those who have who have continued to administer atds for more than 1 year * those who showed normal findings on thyroid function tests while maintaining stable doses of atds in the last 3 months * those who can use wearable devices and smartphone apps to work with during the research period exclusion criteria: * those with heart disease, such as arrhythmia, that can affect heart rate * those who are taking medications that may affect their heart rate * those who researchers deemed unsuitable for participation
pathological crystallization of cholesterol in atherosclerosis

Conditions: Crystallization of Cholesterol in Atherosclerosis

Summary: endarterectomy of the carotid artery procedure will be performed at sheba medical center vascular surgery department, followed by fixation and histology. tissues will then be transferred to weizmann institute of science for observation implementing advanced electron microscopy techniques. finally, joint evaluation of the results will be carried out, in relation to the patient clinical history.

human atherosclerotic tissues will be obtained from the department of vascular surgery, sheba medical center. tissues will be taken from donors undergoing routine endarterectomy procedures.we chose carotid artery as the source for the atheromas, due to its high prevalence and its considerable size.all speciemnts will be studied in cryo-scanning electron microscopy (cryo-sem). tissues will be observed in hydrated vitrified state, after high pressure freezing (hpf) and freeze fracture, as well established in the wis group. samples will be observed at -120°c. cathode-luminescence (cl) detects a luminescence signal induced by electrons in cholesterol crystals and ce condensed states. it will be implemented herein under cryogenic conditions. sample preparation is as for cryo-sem. cryo-fib-sem block face serial imaging allows the acquisition of serial images over large volumes (tens of cubed micrometers), at a relatively high imaging resolution (up to 5nm3 voxel size). volumes of up to 40x40x40 ml will be imaged with a resolution of up to 10nm. the data will be minimally processed and aligned using fiji, reconstructed and manually segmented using avizo lite 9.2.0 software.

Eligibility criteria:
inclusion criteria: * all patients that are being operated on for carotid endarterctomy due to carotid stenosis exclusion criteria: * none
latino semaglutide study

Conditions: Obesity; Obesity; Drug; Overweight or Obesity; Weight Loss; Weight Loss Trajectory; Weight, Body

Summary: the purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. this study may lead to the development of other related medications for assisting people with the disease of obesity.


Eligibility criteria:
inclusion criteria: * self-identify as being of hispanic/latino ethnicity * bmi \>30 * age 18-75 years old * able to provide informed consent before any trial related activities exclusion criteria: * current cancer treatment * diabetes, type 1 or type 2 * eating disorders * medication use targeting the gpl-1 system * in the last 30 days, attempted to lose weight by lifestyle modification alone or with the use of anti-obesity medications resulting in more than 5 pounds of weight loss. * history of bariatric surgery * use of obesogenic medications (including but not limited to steroids, haloperidol, clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and lithium) which cannot be substituted or stopped. * pregnant or planning to become pregnant in the next 8 months * genetic disorders and/or physical or mental handicaps that would limit participation in the study and/or the intensive lifestyle intervention. * any contraindication to semaglutide 2.4 mg including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, hypersensitivity to semaglutide 2.4 mg or any product components. * any known or suspected allergy to semaglutide 2.4 mg or related products * previous participation in this trial, either initial screening or group randomization

Keywords: obesity obesity; drug overweight weight loss weight
identification in obese patients of the mechanism involved in intramuscular lipid accumulation

Conditions: Obesity; Insulin Resistance; Hyperlipidemia

Summary: the study aims to determine in obese patients the implication of intramuscular lipid accumulation in relation with insulin resistance and defect in lipid oxidation.

obese insulin sensitive and obese insulin resistant patients undergo a glucose tolerance test, indirect calorimetry during exercise and muscular biopsy.

Eligibility criteria:
inclusion criteria: * obese patients with a body mass index (bmi) between 30 and 40 kg/m2 * patients who do not practice physical exercise (voorips index \< 9) * age between 40 and 70 years- male gender * fast blood glucose \<1,10 g/l and no hypoglycemic treatment * signed informed consent * social security affiliation * absence of anti vih, anti hepatitis c antibodies, and hbs antigen * normal biological tests * non smoking persons exclusion criteria: * patients who refuse the anti-vih, anti-hepatitis c antibodies, and hbs antigens tests * patients treated by anticoagulant, b blockers, lipopenic, or anti-inflammatory. * patients with a contraindication to muscular exercise (retinopathy, coronaropathy, nephropathy) and to muscular biopsy * allergy to local anaesthetic

Keywords: obese insulin sensitive insulin resistant myotubes lipid accumulation
statins and progression of coronary atherosclerosis in melanoma patients treated with checkpoint inhibitors

Conditions: Melanoma; Atherosclerosis

Summary: this study is a prospective observational study evaluating the natural history of coronary plaque burden in participants with melanoma treated with ici. the study will be conducted at various sites across australia.


Eligibility criteria:
inclusion criteria: * capable of providing informed consent and willing to adhere to all protocol requirements * patients aged \> or equal to 40 years * histologically confirmed melanoma of any stage planned for, commenced, or completed treatment with ici * having acceptable imaging quality deemed by the core laboratory * investigator believes that the participant is willing to adhere to all protocol requirements, including returning for follow up ctca. exclusion criteria: * known clinically manifest cardiovascular disease * female participants must not be pregnant, breastfeeding or plan to become pregnant during the study. * estimated glomerular filtration rate of \<45 ml/min calculated using the chronic kidney disease epidemiology collaboration equation * severe liver disease or cirrhosis * history of any other malignancy within the past 5 years in addition to melanoma with the exception of non-melanoma skin cancers * prognostic factors associated with an expected survival less than 18 months at investigators' discretion (e.g. unresectable brain metastases) * evidence of any other clinically significant non-cardiac disease or condition that, in the opinion of the investigator, would preclude participation in the study * major allergy to iodine * participation in another clinical trial that does not allow participation in multiple trials at the same time
arthroscopic evaluation of cartilage regeneration after opening-wedge high tibial osteotomy

Conditions: Osteo Arthritis Knee

Summary: osteoarthritis of the knee is a common problem causing significant knee pain and disability. medial compartment osteoarthritis is predisposed to by varus deformity of the knee. high tibial osteotomy is a well-established method for treatment of medial unicompartmental knee osteoarthritis and correction of varus deformity.

osteoarthritis is a degenerative joint disease characterized by erosion of the articular cartilage, hypertrophy of the bone at the margins and subchondral sclerosis. osteoarthritis of the knee is a common problem causing significant knee pain and disability. medial compartment osteoarthritis is predisposed to by varus deformity of the knee. high tibial osteotomy is a well-established method for treatment of medial unicompartmental knee osteoarthritis and correction of varus deformity. it is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. the procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space. the methods for اigh tibial osteotomy include opening-wedge osteotomy and closed wedge osteotomy. an opening-wedge osteotomy has become increasingly popular compared to the other technique. one of the disadvantages of this technique is that the plate is placed subcutaneously on the medial aspect of the proximal tibia. many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy. few papers assessed regeneration of the articular cartilage after medial opening-wedge osteotomy.

Eligibility criteria:
inclusion criteria: 1. age younger than 65 years 2. medial joint line tenderness 3. bmi less than 30 4. varus tibiofemoral malalignment 5. range of motion in the knee joint maintained from greater than 100 degrees of flexion to less than 15 degrees of flexion contracture 6. osteoarthritis of the knee with any degree of cartilage damage provided that the cartilage damage in the lateral compartment not exceeding outerbridge grade 2 7. no associated ligamentous functional instability exclusion criteria: 1. age older than 65 years 2. severe lateral compartment osteoarthritis (outerbridge grade 3 or 4) 3. flexion contracture of greater than 15 degrees 4. inflammatory arthritis, post-traumatic osteoarthritis, active knee infection
mobile phone text message program to understand symptoms and improve outcomes in minor head injury patients

Conditions: Head Injury, Minor

Summary: mild traumatic brain injury (mtbi) is frequently seen in the ed, post-concussive symptoms are common post-injury, and few mtbi patients receive treatment or follow-up for these symptoms. cell phones are ubiquitous, text messaging (sms) is a cheap and increasingly common form of communication, potentially allowing for accurate assessment of symptom patterns after mtbi and provision of basic education support . the investigators seek to assess the feasibility of using sms to collect symptoms related to mtbi in patients either discharged from the ed or admitted to the inpatient trauma unit. the investigators also seek to explore how sms-based symptom reports correlate with phone-based follow-up reports at 14 days and whether additional sms-based educational feedback alters daily symptom patterns.

the investigators seek to assess the feasibility of using sms to collect symptoms related to mtbi in patients either discharged from the ed or admitted to the inpatient trauma unit. the investigators also seek to explore how sms-based symptom reports correlate with phone-based follow-up reports at 14 days and whether additional sms-based educational feedback alters daily symptom patterns at 3-months.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of minor traumatic brain injury * english speaking * owns a cell phone with sms exclusion criteria: * critically ill
the microenvironment in barrett's esophagus

Conditions: Barrett Esophagus; Esophageal Adenocarcinoma

Summary: this study aims to elucidate the relationship between the microbiome, inflammation, and the microenvironment in barrett's esophagus (be) and esophageal adenocarcinoma (eac), with the end goal of developing a non-endoscopic testing strategy based on pathogenic factors to identify patients at highest risk for eac. to accomplish this the investigators will enroll 100 patients with known be (50 with dysplasia or eac) and 50 subjects without be undergoing upper endoscopy. prior to endoscopy each subject will undergo three minimally invasive potential screening and surveillance tests: saliva (oral microbiome), breath test (exhaled volatile organic compounds), and tethered capsule sponge sampling (methylated dna markers). the study will evaluate these novel tests in combination with clinical and anthropometric factors to describe an optimal strategy for be screening and monitoring.

the investigators will perform a multi-center cross-sectional study of patients with barrett's esophagus, with and without associated dysplasia or cancer, and controls without be. enrollment of controls will be stratified based on use of proton pump inhibitors (ppis). the investigators plan to enroll an approximate total of 150 subjects: 100 be patients (with or without associated dysplasia or cancer) * 50 subjects with non-dysplastic be * 50 subjects with be and dysplasia or eac 50 controls * 25 controls on ppis (at least once daily) * 25 controls not taking ppis various tests will be performed and samples collected on the day of endoscopy. these tests include: saliva samples, electronic nose device testing, tethered capsule sponge testing, dietary questionnaires, and collection of blood and gastrointestinal biosamples. analyses of this data and samples will then be performed to address the specific aims above.

Eligibility criteria:
inclusion criteria: (for be patients) * history of histologically confirmed be, defined as endoscopically-suspected be with intestinal metaplasia with goblet cells on esophageal biopsies * be length m≥2 * taking proton pump inhibitors at least once daily for 3 months prior to enrollment * age ≥18 exclusion criteria: * history of gastric cancer or esophageal squamous cell cancer * history of gastric or esophageal surgery * use of antibiotics or systemic immunosuppressants within three months prior to the date of endoscopy (intranasal and inhaled steroids are allowed) * known untreated esophageal stricture or uninvestigated dysphagia * inability to give informed consent * (be patients only) history of prior endoscopic therapy for be except a history of prior endoscopic mucosal resection (emr) of focal lesions without subsequent ablative therapy is permitted

Keywords: microenvironment microbiome screening barrett esophagus esophageal adenocarcinoma
the activity of tissue engineering skin substitutes

Conditions: Difficult to Heal Wounds

Summary: the main purpose of this experiment was to evaluate the activity of tissue engineering skin substitutes safety and efficacy studies for the treatment of difficult to heal wounds

this study for 6 months for a single center, open, randomized, controlled clinical trials before and after itself, test contains preliminary screening, treatment and follow-up after discharge of the patient.after treatment in patients with early debridement, in the case of no infection of living tissue engineering skin substitute transplantation, observe the wound healing after transplantation, chronic wound evaluation activity of tissue engineering skin substitutes in the efficacy and safety of wound healing after transplantation.

Eligibility criteria:
inclusion criteria: 1. meet difficult had 1 month or more to heal the wound patients 2. who signed the informed consent of men or women older than 17 (pregnancy) 3. has the ability to care for, has the ability to self signed informed consent, 7 to 17 years old must be signed by the guardian informed consent 4. the process of mental stability, can finish the test exclusion criteria: 1. known allergic to bovine collagen or gao min physique 2. the wound is greater than the10cm×10cm 3. people with mental illness, drug abusers and or other items 4. pregnant women,prepare a pregnancy or breast feeding women 5. 3 months participated in other similar experiment 6. serious infectious disease not controller 7. with surgery, such as severe trauma stress situation 8. can not meet the requirement of the long-term follow-up of patients
efficacy of autologous outer-root-sheath melanocytes transplantation in the treatment of vitiligo

Conditions: Vitiligo

Summary: the purpose of this study is to evaluate the hypothesis that, in patients with stable vitiligo unresponsive to conventional treatments including traditional phototherapy and/or topical steroids, the application of a non-cultured autologous hair follicle outer-root-sheath melanocytes suspension in the area affected by the disease followed by targeted ultraviolet b (uvb) phototherapy can lead to a significant skin repigmentation. to assess the effect of the proposed treatment, a within-subject controlled study involving selected symmetric lesion areas localized to the back of the hands will be conducted.


Eligibility criteria:
inclusion criteria: * presence of symmetric lesions of vitiligo at the back of the hands with an extension \>5cm² * vitiligo lasting at least one year at the backs of both hands * stable vitiligo, defined as vitiligo that presents no evident evolution (appearance of new lesions or increase in the extension of lesions already present) for at least 6 months * suspension for at least two months prior to the enrollment date of any systemic drug for vitiligo such as immunosuppressive treatment (cyclosporine, systemic steroids) or psoralen + ultraviolet a therapy, phototherapy with ultraviolet b, and of any anticoagulant drug * suspension of topical medications for at least 15 days prior to the enrollment date exclusion criteria: * presence of active vitiligo or koebner phenomenon * difference of more than 10% in the extension of symmetrical areas of vitiligo * presence of systemic infections or infections localized to the tissues intended for transplantation * history of infections to the tissues intended for transplantation (herpes simplex, human papillomavirus infections, pityriasis versicolor, pityriasis alba) * presence or history of malignancy * chemotherapy or radiation therapy in progress * history of allergies or adverse reactions to local anesthetics * presence of transmissible diseases (human immunodeficiency virus, hepatitis b and c, human t-lymphotropic virus type i and ii, syphilis, cytomegalovirus, creutzfeldt-jacob, tuberculosis) * women who are pregnant or intend to become pregnant during the study period (including breastfeeding women)

Keywords: vitiligo outer-root-sheath melanocytes hair follicles